Lebrikizumab
Lebrikizumab (TNX-650) is an IgG4 humanized anti-interleukin-13 (IL-13) mAb with anti-itch effects that specifically binds to IL-13 in a non-receptor binding domain and inhibits its function. Lebrikizumab inhibits the IL-13 driven Th2 inflammatory response and blocks the signaling of IL-4Rα/IL-13Rα1. Lebrikizumab can be used for the research of asthma, atopic dermatitis and neuroinflammatory diseases[1][2][3].
Product Specifications
CAS Number
953400-68-5
Product Name Alternative
TNX-650; MILR1444A; RG3637
UNSPSC
12352203
Target
Interleukin Related
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/lebrikizumab.html
Purity
99.90
Solubility
H2O
Smiles
[Lebrikizumab]
Molecular Weight
(145.318 kDa)
References & Citations
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Launched
Isoform
IL-13
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
KLF13 (Krueppel-like Factor 13, Basic Transcription Element-binding Protein 3, BTE-binding Protein 3, Novel Sp1-like Zinc Finger Transcription Factor 1, RANTES Factor of Late Activated T-lymphocytes 1, RFLAT-1, Transcription Factor BTEB3, Transcription Factor NSLP1, BTEB3, NSLP1) (MaxLight 550) discontinued
